Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Lentiviral vectors (LVVs ... number of commercial advanced therapy technologies, from chimeric antigen receptor (CAR) T-cell therapies to ex vivo gene therapies and, earlier last year, the ...

To date, over 40 ADA-SCID patients have been treated with autologous ex-vivo lentiviral gene therapy at the two locations. All patients have survived (100% overall survival) with follow-up up to 5 ...

Capital will fund Castle Creek’s D-Fi Phase 3 clinical trial for patients with dystrophic epidermolysis bullosa through ...

Viral vectors differed amongst studies, with lentiviral vectors being favored in the later trials after ... has provided a deeper understanding of the intricate mechanisms underlying gene therapy in ...

“The early results of this clinical study reveal a new opportunity for gene therapy for hemophilia A that can be offered to all patients, possibly at an early age,” researchers wrote. Findings were ...

10, 2024 — In a single IV injection, a gene therapy targeting ... by using a novel in vivo CRISPR genome editing ... Researchers Discover Potential Mole Reversal Therapy in Rare Condition ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The CONNECT2-EDO51 phase 2 trial looks at PGN-EDO51, an investigational therapy for Duchenne muscular dystrophy (DMD), and is still ongoing in the United Kingdom. The most-read gene therapy ...